Full Year 2023 Investor Presentation
142
Investor presentation
Full year 2023
Solid sales growth driven by Diabetes and Obesity care
Reported annual sales 2019-2023
DKK billion
+17%
12%
14%
15%
16%
88%
86%
84%
85%
2019
1 CAGR for 5-year period
2020
2021
Rare disease
2022
Diabetes and Obesity care
S&D: Sales and distribution; R&D: Research and development
Note: The outlined expected developments are aspirations and not long-term financial targets
7%
93%
2023
السمر
لگیم
Expected development towards 2025
Gross margin
Remain broadly stable
Novo NordiskⓇ
S&D cost ratio
Gradually decline enabled by
attractive sales growth
R&D cost ratio
8
88
Administration
cost ratio
Gradually increase to
expand and diversify pipeline
Decline driven by efficiency
gains
Operating
margin
Remain broadly stableView entire presentation